Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia

Part of Leukemia

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic myelomonocytic leukemia

61 trials tracked for Chronic myelomonocytic leukemia: 5 in phase 3 or 4 and 2 with published results. The most-cited published study has 127 citations.

61Trials tracked
5Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 5 Phase 2 43 Phase 1 6 Other / NA 7
  1. Phase 3 Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Completed · 127 cited
  2. Phase 3 Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML Completed · 94 cited
  3. Phase 3 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed
  4. Phase 3 Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed
  5. Phase 3 Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML Completed
  6. Phase 2 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed
Show 44 more trials
  1. Phase 2 Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed
  2. Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Completed
  3. Phase 2 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia Completed
  4. Phase 2 Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Completed
  5. Phase 2 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed
  6. Phase 2 Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Completed
  7. Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  8. Phase 2 Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Completed
  9. Phase 2 Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Completed
  10. Phase 2 A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). Completed
  11. Phase 2 Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed
  12. Phase 2 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed
  13. Phase 2 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed
  14. Phase 2 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Completed
  15. Phase 2 MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia Completed
  16. Phase 2 Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant Completed
  17. Phase 2 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia Completed
  18. Phase 2 Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed
  19. Phase 2 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed
  20. Phase 2 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed
  21. Phase 2 Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Completed
  22. Phase 2 Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Completed
  23. Phase 2 Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant Completed
  24. Phase 2 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed
  25. Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  26. Phase 2 Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Completed
  27. Phase 2 Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Completed
  28. Phase 2 Oral Clofarabine Study in Patients With Myelodysplastic Syndrome Completed
  29. Phase 2 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies Completed
  30. Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Completed
  31. Phase 2 Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Completed
  32. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  33. Phase 2 Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Completed
  34. Phase 2 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed
  35. Phase 2 WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  36. Phase 2 Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders Completed
  37. Phase 2 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed
  38. Phase 2 Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed
  39. Phase 2 Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome Completed
  40. Phase 2 A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia Completed
  41. Phase 2 Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Completed
  42. Phase 2 Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML) Completed
  43. Phase 1 Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS Completed
  44. Phase 1 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients Completed

Showing the 50 most-cited and recently-updated of 61 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Chronic myelomonocytic leukemia: what the trials found

Fludarabine has been evaluated in multiple clinical trials for the treatment of chronic myelomonocytic leukemia (CMML) [1, 10, 20]. In one study involving a cohort with varying tacrolimus prophylaxis durations, 33% to 42% of participants were able to discontinue prophylactic tacrolimus, with only one instance of Grade III-IV acute GVHD reported in the 90-day cohort 20.

Azacitidine has been investigated across several trials for CMML [12, 14, 19]. In a large Phase 3 trial (N=454), Azacitidine did not show statistically significant differences in Event-Free Survival (p=0.557), Overall Survival (p=0.152), or Time to AML Transformation (p=0.562) compared to the control group 3.

Guadecitabine was evaluated in a Phase 3 trial (N=417); while it did not show statistically significant differences in Overall Survival (p=0.6063), results were reported for transfusion independence and marrow complete response rates 6. Other established interventions include Glasdegib 5 and ASTX727, the latter of which was evaluated regarding LINE-1 demethylation percentages and Grade 3 or higher treatment-emergent adverse events in MDS/CMML patients 4.

A supersaturated calcium phosphate rinse was shown to maintain a consistent duration of severe oral mucositis (WHO Grade 3 or 4) at 4.5 for the study population 7.

Recent results — preliminary, needs further review

  • DEC-205/NY-ESO-1 Fusion Protein CDX-1401 was evaluated in a Phase 1 trial (N=8) 2.
  • Fludarabine phosphate was investigated in a Phase 2 trial (N=62) 9.
  • Donor Lymphocytes were evaluated in a Phase 2 trial (N=55) 8.

For the clinician treating this condition

  • Fludarabine is established as an intervention for CMML, with data available regarding its use alongside tacrolimus prophylaxis [1, 10, 20].
  • Azacitidine has been tested in large-scale trials; however, significant improvements in EFS, OS, or time to AML transformation were not observed in the primary Phase 3 study reported [3, 12, 14, 19].
  • Guadecitabine showed no statistically significant difference in Overall Survival compared to control groups in a large trial 6.

AI synthesis of 9 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis
Allergy & Immunology Sys. Review
Case report and review: azacytidine plus ruxolitinib in connective tissue disease with CMML and myelofibrosis A single patient found relief from blood cancer with a new drug combo
This case report and literature review describes a 52-year-old male with connective tissue disease, chronic myelomonocytic leukemia, and mye…
One man with blood cancer saw his fever and anemia improve after two years on a specific drug mix, offering a glimpse into potential new tre…
Frontiers May 14, 2026
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts
Oncology RCT
Decitabine versus hydroxyurea in advanced chronic myelomonocytic leukemia shows survival differences linked to baseline counts Keeping Blood Cell Counts Low in Leukemia Predicts Who Lives Longer
This randomized controlled trial (RCT) enrolled 120 patients with advanced proliferative chronic myelomonocytic leukemia (CMML) comparing de…
In chronic myelomonacytic leukemia, keeping abnormal blood cells low after treatment predicts who lives longer than bone marrow changes alon…
Apr 18, 2026
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine
Hematology
Case report: CMML initially diagnosed as ITP in one patient, stabilized with decitabine A single case shows leukemia can initially look like a different blood disorder
A case report describes one patient initially diagnosed with immune thrombocytopenia (ITP) who was later found to have chronic myelomonocyti…
A single case shows leukemia can initially look like a different blood disorder, so doctors must watch for hidden mutations when standard tr…
Frontiers Apr 1, 2026

Research across Leukemia

Related studies from across the Leukemia family.

Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance
Cardiology Sys. Review
Early genetic diagnosis of inherited bone marrow failure syndromes facilitates timely transplant and lifelong surveillance Genetic Factors May Influence Diagnosis of Bone Marrow Failure
This narrative review explores the pathogenesis, clinical manifestations, and management of pediatric patients with inherited bone marrow fa…
Genetic factors can be the hidden cause of bone marrow failure in children, making early genetic testing vital for proper treatment and plan…
Frontiers Oct 28, 2026
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia
Oncology Meta-analysis
Positive LSC status is associated with inferior survival outcomes in patients with acute myeloid leukemia Leukemia Stem Cell Counts Help Doctors Predict Patient Survival Outcomes
This systematic review and reconstructed individual patient data meta-analysis analyzed survival outcomes in patients with acute myeloid leu…
Testing for specific leukemia stem cells can help doctors predict how well a patient will do during treatment.
Oct 27, 2026
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm
Oncology Sys. Review
Icotinib treatment for EGFR-mutated NSCLC may be associated with rare treatment-related myeloid neoplasm Icotinib Treatment for Lung Cancer Linked to Rare Blood Condition
This case report and literature review describes a 75-year-old female with lung adenocarcinoma treated with icotinib. The report identifies …
A rare case of acute myeloid leukemia was linked to a specific lung cancer treatment, highlighting the need for regular blood monitoring.
Frontiers Oct 22, 2026
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Oncology RCT
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
Oct 15, 2026
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds
Primary Care & Family Medicine Meta-analysis
VRE Prevalence 18.4% in Hematologic Malignancy Patients, Pooled Meta-Analysis Finds Vancomycin-resistant Enterococcus is common in patients with certain blood cancers
This meta-analysis of 120 studies estimates the pooled prevalence of vancomycin-resistant Enterococcus (VRE) in patients with hematological …
A large review of 120 studies shows that nearly 1 in 5 patients with leukemia or lymphoma carry a resistant strain of bacteria.
Frontiers Oct 15, 2026
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML
Oncology RCT
Low-dose chemotherapy shows no difference in remission but worse outcomes in KIT-mutated AML Low-dose chemotherapy shows similar results for some children with leukemia
This retrospective secondary analysis of a multicenter randomized controlled trial evaluated low-dose chemotherapy (LDC) versus standard-dos…
A study of children with a specific type of leukemia found that lower doses of chemotherapy can be as effective as standard doses for many p…
Oct 9, 2026
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients
Hematology Meta-analysis
BTK inhibitors do not significantly increase second primary malignancy risk in B-cell lymphoma patients BTK inhibitors do not appear to cause second primary cancers
This meta-analysis of 9337 patients found that BTK inhibitors do not significantly increase the risk of second primary malignancies compared…
New data suggests that a common class of drugs used to treat certain blood cancers does not increase the risk of developing new cancers.
Oct 1, 2026
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection
Drug Pipeline Meta-analysis
Dasatinib therapy in pediatric ALL may cause chylothorax and Bartonella henselae infection Dasatinib May Cause Chylothorax and Cat-Scratch Disease in Leukemia
This case report and systematic review describes a 14-year-old boy with Ph+ acute lymphoblastic leukemia treated with dasatinib who develope…
A 14-year-old on dasatinib for leukemia developed chylothorax and cat-scratch disease, a rare double complication.
Frontiers Sep 29, 2026
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL
Oncology RCT
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL Trial shows blinatumomab improves survival for children with high-risk leukemia
Blinatumomab significantly improves 4-year event-free survival in children with high-risk B-cell ALL compared to standard chemotherapy.
A new trial shows that blinatumomab helps more children with high-risk B-cell leukemia stay healthy compared to standard chemotherapy.
Sep 17, 2026
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL
Pediatrics Meta-analysis
Busulfan-based conditioning favors survival in AML while TBI yields better outcomes in ALL Busulfan Shows Survival Benefits for Patients with Acute Myeloid Leukemia
This meta-analysis of 26 studies compared Busulfan-based conditioning to total body irradiation for children and young adults undergoing hem…
Busulfan may offer better survival for certain leukemias while reducing long-term side effects like growth issues and cataracts in young pat…
Frontiers Sep 17, 2026
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia
Pediatrics Meta-analysis
Exercise interventions improve bone mineral density, cardiorespiratory endurance, and quality of life in children with acute leukemia Exercise May Help Kids With Leukemia Feel and Move Better
This best evidence summary synthesizes 16 systematic reviews and 2 clinical practice guidelines regarding exercise interventions for childre…
Exercise may improve bone strength, fitness, and quality of life in children with acute leukemia, a new evidence summary suggests.
Frontiers Sep 17, 2026
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML
Hematology Meta-analysis
MRG mutations correlate with worse overall survival and lower remission in NPM1-mutated AML Specific gene mutations linked to worse outcomes in certain leukemia
This meta-analysis of 4,363 patients found that MRG mutations (such as ASXL1, BCOR, and EZH2) are associated with inferior overall survival …
New data shows that specific gene mutations can predict poorer survival and lower remission rates for patients with a specific type of leuke…
Sep 1, 2026

Questions about Chronic myelomonocytic leukemia

Can ruxolitinib help CMML patients who also have connective tissue disease?

A specific case report shows that combining azacytidine with ruxolitinib helped a patient with connective tissue disease, CMML, and myelofibrosis by reducing fever, correcting high monocyte counts, and improving anemia.

Full answer →
What happens if a CMML patient is first diagnosed with ITP?

CMML can be misdiagnosed as ITP when thrombocytopenia is the first symptom; immunosuppressive therapy may temporarily raise platelets, but the underlying CMML progresses. Decitabine can stabilize the condition.

Full answer →